NCT02189772View on ClinicalTrials.gov

Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

ADHD, Predominantly Inattentive Type

Interventions

DRUG

Metadoxine extended release

MG01CI

DRUG

Placebo

Inactive drug

Trial Locations (6)

Unknown

Rambam Medical Center, Haifa

Hadassah-Hebrew University Medical Center,, Jerusalem

Geha Medical Centre, Petah Tikva

The Chaim Sheba medical center, Tel Hashomer, Ramat Gan

Assaf Harofeh MC, Zrifin

Shalvata Mental Health Center, Hod HaSharon

All Listed Sponsors

lead

Alcobra Ltd.

INDUSTRY

NCT02189772 - Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects | Biotech Hunter | Biotech Hunter